TABLE 1.

Baseline characteristics of the three groups

	Healthy control (n = 12)	Myasthenia gravis (n = 11)	Graves' orbitopathy (n = 6)
Age, years	41.0 ± 15.9	52.5 ± 15.9	46.7 ± 14.0
Gender
Male	5 (42%)	7 (64%)	3 (50%)
Female	7 (58%)	4 (36%)	3 (50%)
Disease onset
<3 months	‐	5 (45%)	3 (50%)
>1 year	‐	6 (55%)	3 (50%)
Medication
Pyridostigmine	‐	10 (91%)	‐
Prednisone	‐	6 (55%)	2 (33%)
Other immunosuppressants	‐	1 (9%)	‐
MG phenotype
Ocular	‐	7 (64%)	‐
Generalized	‐	4 (36%)	‐
Anti‐TSH‐R antibodies	‐	‐	6 (100%)
Anti‐AChR antibodies	‐	10 (91%)	‐